A protein biomarker predicts response to immunomodulatory drug (IMiD) therapy for multiple myeloma (MM). At PMO Live 2015, A. Keith Stewart, MB, ChB, Consultant, Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, presented a case study illustrating the relative merits of an MM-specific gene panel to test for targetable [ Read More ]
Biomarkers have a promising role in the early detection and risk stratification of colonic neoplasia, lung cancer, and breast cancer said presenters at PMO Live 2015. Molecular Biomarkers: Colorectal Cancer The vast majority of screening colonoscopies are negative for significant lesions of advanced adenomas or carcinoma in average-risk and even [ Read More ]
Increasingly, genomic alterations are being recognized and targeted for clinical trials. Improving clinical trial accrual in this environment may require multiple histology basket trials that increase the percentage of patients with “actionable†alterations, said Funda Meric-Bernstam, MD, at PMO Live 2015. The implications for the use of predictive markers for [ Read More ]
Comprehensive genomic profiling of tumors can identify more targeted treatment options than “hots pot†tests and enable innovative trial designs, said Roman Yelensky, PhD, at PMO Live 2015. Unvalidated diagnostic tests with poor accuracy represent a challenge to informed targeted treatment decisions for patients with cancer. Therapies targeting the genomic [ Read More ]
Many therapeutic agents target HER2-positive breast cancer. Unfortunately, patient selection for these agents has not been refined, so all HER2-positive patients receive them. In estrogen receptor (ER)-positive disease, new agents improve the response to hormone-targeted therapies, but again, the appropriate patients for targeted agents have not been defined. “Because many [ Read More ]
Genetic tumor profiling, immune profiling, and immunohistocompatibility expression profiling are performed routinely at Yale Cancer Center for patients diagnosed with cancer. The results are presented to the multidisciplinary Molecular Tumor Board, which meets weekly to make treatment decisions. The following case exemplifies a personalized medicine approach and was presented by [ Read More ]
